- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04756830
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This is an open-label uncontrolled study in which all participants will receive two doses of the inactivated adsorbed vaccine against COVID-19, and will be followed up for safety and immunogenicity analysis for 24 months. This study will assess safety and immunogenicity of the inactivated vaccine adsorbed against COVID-19 (CoronaVac) in a population of healthy individuals older than 18 years of age.
The estimated number of participants is 1200. Participants will be recruited within 3-4 months. The total duration of the study is estimated to be 30 months after recruitment begins.
The participants will remain in the study for approximately 24 months. The study will be carried out at the clinical research center of the D'Or Institute for Research and Education (IDOR) located at the Hospital Glória D'Or, in the city of Rio de Janeiro, RJ, Brazil
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Rio De Janeiro, Brazylia, 22211-230
- Hospital Gloria D'Or - Hospitais Integrados da Gavea S/A
-
Rio De Janeiro, Brazylia, 22281100
- D'Or Institute for Research and Education
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adults 18 years of age or older;
- Agree with study procedures after reading and signing the Informed Consent Form
Exclusion Criteria:
- Pregnancy (confirmed by positive β-hCG test), breastfeeding and / or expressing intention to have sexual practices with reproductive potential without using contraceptive methods in the three months following vaccination
- Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- Diseases with impaired immune system including: neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- Behavioral, cognitive or psychiatric illness that, in the opinion of the principal investigator or his medical representative, affects the participant's ability to understand and collaborate with the requirements of the study protocol
- Any alcohol or drug abuse in the last 12 months prior to inclusion in the study that has caused medical, professional or family problems, as indicated by clinical history;
- History of severe allergic reaction or anaphylaxis to the vaccine or components of the study vaccine;
- History of asplenia;
- Participation in another clinical trial with product administration under investigation during the six months prior to its inclusion in the study or scheduled participation in another clinical trial in the two years following inclusion;
- Previous participation in a COVID-19 vaccine evaluation study or previous exposure to a COVID-19 vaccine;
- Use of immunosuppressive therapies six months prior to inclusion in the study or its scheduled use within two years of inclusion. Immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, among others.
- Have received an immunosuppressive dose of corticosteroids in the last three months prior to inclusion in the study or scheduled administration of an immunosuppressive dose of corticosteroids for the three months following inclusion in the study. The dose of corticosteroids considered immunosuppressive is equivalent to prednisone at a dose of 20 mg / day for adults, for more than a week. The continuous use of topical or nasal corticosteroids is not considered immunosuppressive;
- Have received blood products (transfusions or immunoglobulins) in the last three months before inclusion in the study, or scheduled administration of blood products or immunoglobulin in the two years following inclusion in the study;
- Suspected or confirmed fever within 72 hours prior to vaccination or axillary temperature greater than 37.8 ° C * on the day of vaccination (inclusion may be postponed until the participant completes 72 hours without fever);
- Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be postponed until the participant completes 72 hours without symptoms or the diagnosis is ruled out);
- Have received vaccine with live attenuated virus in the last 28 days or inactivated vaccine in the last 14 days prior to their inclusion in the study, or have immunization scheduled for the first 28 days after their inclusion in the study;
- History of bleeding disorders (for example, deficiency of clotting factors, coagulopathy, platelet dysfunction), or previous history of bleeding or significant bruising after IM injection or venipuncture.
- Any other condition that, in the opinion of the principal investigator or his medical representative, could jeopardize the safety or rights of a potential participant or that would prevent him from complying with this protocol.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Inny: Vaccination
All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
|
Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Frequency of local and systemic adverse reactions in the first 7 days after immunization
Ramy czasowe: Seven days after each immunization
|
Frequency of solicited and unsolicited local and systemic adverse reactions in the first 7 days after vaccination per age group (18-59 years old and 60 years old or older), attributed to the vaccine after causality assessment
|
Seven days after each immunization
|
Seroconversion rates
Ramy czasowe: Two weeks after the second immunization
|
Seroconversion rates in the second week after the second dose of the vaccine per age group (18-59 years and 60 years old or older).
|
Two weeks after the second immunization
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Frequency of adverse reactions up to 28 days after immunization
Ramy czasowe: 28 days after the second immunization
|
Frequency of unsolicited local and systemic adverse reactions up to 28 days after the second dose of the vaccine per age group (18-59 years old and 60 years old or older), attributed to the vaccine after causality assessment
|
28 days after the second immunization
|
Frequency of severe adverse events
Ramy czasowe: Up to 12 months after first immunization
|
Frequency of severe adverse events after vaccination, attributed to the vaccine after causality assessment
|
Up to 12 months after first immunization
|
Frequency of adverse events of special interest
Ramy czasowe: Up to 12 months after first immunization
|
Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine
|
Up to 12 months after first immunization
|
Cell-mediated immune response
Ramy czasowe: At inclusion and 4 weeks after the second vaccination
|
Cell-mediated immune response at inclusion and four weeks after the second vaccination per age group (18-59 years old and 60 years old or older).
|
At inclusion and 4 weeks after the second vaccination
|
Frequency of detection of antibodies against SARS-CoV-2
Ramy czasowe: At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Frequency of detection of antibodies against SARS-CoV-2 at inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second dose of the vaccine against COVID-19.
|
At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Geometric mean titer of neutralizing antibodies
Ramy czasowe: At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Geometric mean titer of neutralizing antibodies against SARS-CoV-2 at inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second dose of the vaccine against COVID-19.
|
At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Frequency of confirmed cases of COVID-19
Ramy czasowe: Up to 24 months after inclusion
|
Frequency of confirmed cases of COVID-19 per age group (18-59 years old and 60 years old or older) over 24 months.
|
Up to 24 months after inclusion
|
Frequency of SARS-CoV-2 variants of concern (VOC)
Ramy czasowe: Up to 24 months after inclusion
|
Frequency of SARS-CoV-2 variants of concern (VOC) in confirmed cases of COVID-19.
|
Up to 24 months after inclusion
|
Humoral and cellular immune response
Ramy czasowe: Up to 24 months after inclusion
|
Humoral and cellular immune response in confirmed cases of COVID-19
|
Up to 24 months after inclusion
|
Współpracownicy i badacze
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- IDOR_VAC_01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na COVID-19
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkJeszcze nie rekrutacjaSyndrom po COVID-19 | Długi COVID | Długi Covid19 | Stan po COVID-19 | Syndrom post-COVID | Stan po COVID-19, nieokreślony | Stan po Covid-19Holandia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...ZakończonyOstre następstwa COVID-19 | Stan po COVID-19 | Długi-COVID | Przewlekły zespół Covid-19Włochy
-
Indonesia UniversityRekrutacyjnySyndrom po COVID-19 | Długi COVID | Stan po COVID-19 | Syndrom post-COVID | Długi COVID-19Indonezja
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutacyjnyCovid-19 pandemia | Covid-19 szczepionki | Choroba wirusowa COVID-19Indonezja
-
Yang I. PachankisAktywny, nie rekrutującyInfekcja dróg oddechowych COVID-19 | Zespół stresu wywołany przez COVID-19 | Niepożądana reakcja na szczepionkę COVID-19 | Choroba zakrzepowo-zatorowa związana z COVID-19 | Zespół po intensywnej terapii COVID-19 | Udar związany z COVID-19Chiny
-
Massachusetts General HospitalRekrutacyjnyZespół po ostrym COVID-19 | Długi COVID | Ostre następstwa COVID-19 | Długi COVID-19Stany Zjednoczone
-
Medisch Spectrum TwenteZiekenhuisgroep Twente; University of TwenteAktywny, nie rekrutujący
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... i inni współpracownicyRekrutacyjnyObserwacja kohortowa epidemii i neuroobrazowanie pacjentów podczas pierwszej fali COVID-19 w ChinachCOVID-19 | Syndrom po COVID-19 | Po ostrym COVID-19 | Ostra choroba COVID-19Chiny
-
National Institutes of Health Clinical Center (CC)ZakończonyOstre i długoterminowe skutki COVID-19 na zapalenie ogólnoustrojowe | Ostre i długoterminowe skutki COVID-19 na czynność płuc | Ostre i długoterminowe skutki COVID-19 na czynność serca | Ostre i długoterminowe skutki COVID-19 na czynność nerek | Ostre i długoterminowe skutki COVID-19 na funkcjonowanie...Stany Zjednoczone
Badania kliniczne na Adsorbed COVID-19 (inactivated) Vaccine
-
Karamanoğlu Mehmetbey UniversityRekrutacyjny
-
AstraZenecaZakończonyCOVID-19Zjednoczone Królestwo
-
Hasanuddin UniversityChulalongkorn UniversityZakończony
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...ZakończonyKoronawirus infekcjaFrancja
-
AstraZenecaZakończonyCovid-19Zjednoczone Królestwo
-
University of Texas at AustinNieznanyNiepewna żywnośćStany Zjednoczone
-
University of AberdeenJeszcze nie rekrutacjaCovid19 | Zatorowość płucna
-
Thomas Jefferson UniversityNemoursAktywny, nie rekrutujący
-
Assaf-Harofeh Medical CenterZakończony
-
University of PennsylvaniaPublic Health Management CorporationZakończony